# OnCo record cd20 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/cd20/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "cd20" ;
  schema:name "CD20"@en ;
  schema:description "CD20 is a B-cell marker; rituximab against it was the first antibody approved for cancer, in 1997."@en ;
  schema:url <https://onco.cc/targets/cd20/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/CD20>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7315>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000156738>, <https://www.uniprot.org/uniprotkb/P11836/entry>, <https://www.ncbi.nlm.nih.gov/gene/931> ;
  owl:sameAs <http://www.wikidata.org/entity/Q5009796> ;
  schema:citation <https://en.wikipedia.org/wiki/CD20>, <https://doi.org/10.1182/blood-2008-08-175208> ;
  onco:tag "antibody-target" ;
  schema:alternateName "MS4A1" ;
  onco:targetClass "surface-antigen" ;
  onco:firstDescribed "1988"^^xsd:gYear ;
  onco:related <https://onco.cc/biomarkers/cd20-expression/> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/ibritumomab-tiuxetan/>, <https://onco.cc/drugs/ofatumumab/>, <https://onco.cc/drugs/rondecabtagene-autoleucel/>, <https://onco.cc/drugs/tqb2825/>, <https://onco.cc/drugs/zamtocabtagene-autoleucel/>, <https://onco.cc/drugs/azd5492/>, <https://onco.cc/drugs/jnj-90014496/> ;
  onco:companies <https://onco.cc/companies/leah-labs/>, <https://onco.cc/companies/lyell-immunopharma/>, <https://onco.cc/companies/poseida-therapeutics/> ;
  onco:trials <https://onco.cc/trials/nct07284433/> .